Paradromics Inc.

I’m recording a conversation with Matt Angle on building Paradromics Inc. this Friday - we have a few open slots , stop by if you’re in the Bay Cohosting with my good friend Andrew C?té and Hyperstition Incorporated

Reminder! Today is Neurotech Day of the ALS ONE and EverythingALS Annual #ALSResearchSymposium. Join CEO Matt Angle at the BCI discussion starting at 12:30 PM EST, where he will be discussing Paradromics pre-clinical data and our work towards our clinical trials next year! Register for free and join virtually: https://lnkd.in/gi2yUywH #ALS #ALSconference #ALSGlobalSymposium #ALSVirtualSymposium #ALSONEResearchSymposium

This Friday is Neurotech Day (Day 3) of the ALS ONE and EverythingALS Annual #ALSResearchSymposium! Starting at 12:30 PM EST, Paradromics founder and CEO Matt Angle will join a roundtable discussion with other BCI industry leaders, including: - Kurt Haggstrom at Synchron - Romina Nejad at Neuralink - Nick Ramsey at UMC Utrecht - Sergey Stavisky at University of California, Davis/Delegates - Benjamin Rapoport at Precision Neuroscience - Rob Franklin at Blackrock Neurotech - Jessica Kelemen at iBCI-CC ?? This event officially starts tomorrow! Register for free and join virtually: ??https://lnkd.in/gi2yUywH #ALS #ALSconference #ALSGlobalSymposium #ALSVirtualSymposium #ALSONEResearchSymposium

Paradromics was pleased to attend the first inaugural New York Brain Computer Interface Symposium. Our CSO Vikash Gilja participated in the BCI Startup Spotlight, moderated by Sarah McBride of Bloomberg,?commenting on how BCI advances in concert with innovations in AI & data science. #NYBCI24 With Synchron, Precision Neuroscience, Blackrock Neurotech, Science and Meta / CTRL-labs.

The Paradromics team rallied this past weekend for the The ALS Association’s #WalktoDefeatALS. Thank you to everyone who participated in supporting the #ALS community!

We resonate with the balance Sarah McBride outlines in her Bloomberg News BCI article. BCI companies must first build products grounded in medical science to receive regulatory approval, while pushing technology boundaries. We appreciate the inclusion of Paradromics in the foremost group of startups, “working toward a sleeker generation of wireless devices that treat ailments such as ALS, blindness and paralysis.” https://lnkd.in/gmbTqyB5

MassDevice unpacks the Morgan Stanley estimates for a massive $400bn US BCI market.?Paradromics was highlighted as a pivotal player making regulatory progress, “The company?already has two FDA breakthrough device designations for its Connexus system…and was accepted into the FDA Total Product Life Cycle Advisory (TAP) program.” More details here: https://lnkd.in/gcdzmwiu

The Morgan Stanley BCI analysis estimates a TAM of $400bn in the US alone. Paradromics is excited to be building the leading BCI platform. With the ability to improve suffering from a wide variety of diseases including ALS, spinal cord injury, stroke, MS, cerebral palsy, limb amputation, epilepsy, and depression - we agree this new medtech market will be massive.

Matt Angle and Vikash Gilja weigh in on how the “US sets the pace for implantable brain–computer interfaces” in this Nature Magazine article.?With Paradromics in FDA discussions outlining how to gain approval - Matt says, “This is one of the biggest questions right now: how do we think about clinical endpoints in a pivotal study?” https://lnkd.in/gqPDNHUB

?? Every 90 minutes a person in this country is diagnosed with ALS and every 90 minutes another person will lose their battle against this disease. That’s why we are participating in the Walk to Defeat ALS. To learn more about the event and to help the Paradromics team reach our fundraising goal, visit our team page here: https://lnkd.in/gyxCqR-B The Walk to Defeat ALS Austin is Saturday, October 19, 2024, at Concordia University. Help us take steps toward a world without ALS! #WalktoDefeatALS